Image of veins running throughout the body

Protein Marker Discovered for Vascular Repair

ABCG2 could lead to new therapies for repairing damaged blood vessels and treating a variety of diseases

Written byIndiana University School of Medicine
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Researchers have discovered a protein marker to help identify cells able to repopulate in patients with damaged blood vessels. Their findings, recently published in Circulation, could lead to new therapies for people with endothelial dysfunction, a type of disorder that contributes to coronary artery disease that may occlude with plaque and lack ability to carry sufficient blood into the heart tissue causing a heart attack.

“This study is the first to establish that a single, prospective marker identifies vascular clonal repopulating endothelial cells (CRECs)," said Chang-Hyun Gil, PhD, MS, assistant research professor of surgery at the Indiana University School of Medicine and co-first author of the study. “These exciting findings could lead to new cell therapies for repair of damaged vessels for patients.”

Lab manager academy logo

Biosafety and Biosecurity Course

Get training in Biosafety and Biosecurity and earn CEUs.

One of over 40 IACET-accredited courses in the Academy.

The researchers analyzed the potential of endothelial cells, which make up the protective inner layer of blood vessels, that express a protein called ABCG2 to make colonies, self-renew and form vessels. These cells could form new blood vessels and contributed to the repair of heart tissue blood vessels after a heart attack.

“By analyzing the genes and proteins in these cells, we identified specific pathways involved in blood vessel formation and tissue regeneration,” Gil said. “We discovered that ABCG2 involved in blood vessel development are more active in these cells compared to others, suggesting these specific endothelial cells have the potential to be used in repairing damaged blood vessels. AbcCRECs are becoming an important cell type to be considered for use in human patients suffering from a variety of diseases such as peripheral arterial disease, diabetes, diabetic proliferative retinopathy, acute kidney disease and cardiovascular disease.”

“It is particularly important that this protein marker identified the CRECs in both mouse and human subjects,” said Mervin C. Yoder, MD, Distinguished Professor Emeritus at the IU School of Medicine and a professor of surgery at the University of Pittsburgh. “Few markers have been found that permit prospective isolation of endothelial cells with reparative properties in both mice and humans, making these findings exciting for future study.”

The team has been studying these types of endothelial cells for more than seven years. Further experiments and studies are needed to better understand the functions and mechanisms of AbcCRECs. This will help in developing methods to apply these cells in treating vascular damage and diseases. Additionally, clinical trials are required to validate the therapeutic efficacy of AbcCRECs and explore how to apply the treatment to patients.

Interested in life sciences?

Subscribe to our free Life Sciences Newsletter.

Is the form not loading? If you use an ad blocker or browser privacy features, try turning them off and refresh the page.

By subscribing, you agree to receive email related to Lab Manager content and products. You may unsubscribe at any time.

-Note: This news release was originally published on the Indiana University School of Medicine website. As it has been republished, it may deviate from our style guide.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - May/June 2025

The Benefits, Business Case, And Planning Strategies Behind Lab Digitalization

Joining Processes And Software For a Streamlined, Quality-First Laboratory

Lab Manager May/June 2025 Cover Image